Auriga Research signs strategic MoU with San Francisco Research Institute

New Delhi: Auriga Research Private Limited, a leading Contract Research Organization (CRO), has entered into a strategic Memorandum of Understanding (MoU) with San Francisco Research Institute (SFRI), a US-based healthcare research and innovation organization.

This collaboration aims to strengthen global clinical research, promote AI-integrated healthcare solutions, and expand access to compliant wellness products across India, the United States, and Africa.

The partnership outlines a joint framework to support clinical trials, regulatory pathways, digital health innovation, and international business development. It brings together Auriga’s strong infrastructure and expertise in India and Asia with SFRI’s global capabilities across North America, Europe, and Africa.

Key outcomes of the collaboration include:

• Joint clinical trials using AI for patient recruitment, monitoring, and analytics

• Auriga to lead clinical operations, data management, and regulatory execution in India

• SFRI to drive client engagement and Market expansion in the US, Japan, and Europe

• Auriga to provide eCRF systems, analytics tools, and Indian IT vendor support for global trials

• Co-development of AI-based platforms for research, compliance, and market readiness

• Regulatory support for product launches in India, US, and Africa

• SFRI to support promotion and distribution of SNEC30, Ningen in the US and Africa

• Auriga to manage business development in India and Asia; SFRI in North America and Africa

• Joint training programs on Good Clinical Practices (GCP), Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP), Good Documentation Practices (GDP), and other auditing and compliance standards specific to healthcare, pharmaceuticals, and regulatory science

• Co-development of new formulations and wellness products for global markets

• Joint applications for grants and funded clinical research projects

• SFRI to connect Auriga with marketers and public health agencies in Africa for expansion

Commenting on the collaboration, Dr. Saurabh Arora, Managing Director of Auriga Research, stated:
“This strategic partnership with San Francisco Research Institute reflects our commitment to advancing global standards in clinical research and healthcare innovation. By leveraging our strengths in regulatory science, AI-driven trials, and product development, we aim to expand access to safe, effective, and globally compliant health solutions across India, the US, and Africa. It will also help identify untapped opportunities in North America, Europe, Asia-Pacific, and other emerging markets.”

San Francisco Research Institute will also support regulatory strategy, public health collaboration, and commercial partnerships in markets such as Nigeria and the US. This includes enabling product registration with national health agencies, connecting Auriga to distributors and marketers, and directly supporting sales outreach and supply chain strategies.

Dr. John Ademola, CEO of San Francisco Research Institute, said:
“This partnership combines Auriga’s clinical research expertise with our strengths in AI and regulatory capabilities to accelerate the development of compliant, patient-centric health innovations. It marks a strategic step toward bridging global regulatory ecosystems and scaling evidence-based wellness solutions across geographies by managing regulatory submissions and ensuring compliance with agencies such as the FDA, EFSA, TGA, and others.”

The two organizations will jointly expand their Research Training Program through both digital platforms and in-person sessions, while also co-developing new products and AI applications for healthcare. Additionally, they will pursue government and foundation-funded projects to further their impact on global health systems.

This MoU underscores a shared commitment to building a globally integrated, innovation-driven healthcare ecosystem. It strengthens Auriga Research’s positioning in international wellness and digital health markets and aligns with India’s growing role in the export of health-tech and evidence-based solutions.